作者
Anthony H Harris, Suzanne R Hill, Geoffrey Chin, Jing Jing Li, Emily Walkom
发表日期
2008/9
期刊
Medical Decision Making
卷号
28
期号
5
页码范围
713-722
出版商
SAGE Publications
简介
Objective . To analyze the relative influence of factors in decisions for public insurance coverage of new drugs in Australia.Data Sources. Evidence presented at meetings of the Australian Pharmaceutical Benefits Advisory Committee (PBAC) that makes recommendations on coverage of drugs under Pharmaceutical Benefits Scheme.Study Selection. All major submissions to the PBAC between February 1994 and December 2004 (n = 858) if one of the outcomes measured was life year gained (n=138) or quality-adjusted life years (QALYs) gained (n=116).Results. Clinical significance, cost-effectiveness, cost to government, and severity of disease were significant influences on decisions. Compared to the average submission, clinical significance increased the probability of recommending coverage by 0.21 (95% confidence interval [CI] 0.02 to 0.40), whereas a drug in a life-threatening condition had an increased …
引用总数
学术搜索中的文章
AH Harris, SR Hill, G Chin, JJ Li, E Walkom - Medical Decision Making, 2008